World Journal of Nuclear Medicine · 2018 · 18 citations · 31 references
MedicineOncologyUrologyBone ScintigraphyDiagnostic ImagingMetastasisCancer StagingProstate CancerProstate Cancer ImagingProstate ImagingTumor StagingUrologic Cancer DiagnosisDistant Metastasis DetectionDistant Nodal MetastasisExtraprostatic Extension AssessmentLymph Node MetastasesProstate Cancer Risk StratificationProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen Positron Emission TomographyPsma-pet Imaging
Current imaging for prostate cancer (PCa) had limitations for risk stratification and staging. Magnetic resonance imaging frequently underestimated lymph node metastasis while bone scintigraphy often had diagnostic dilemmas. Prostatic-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) has been remarkable in PCa recurrence. Ninety-seven PSMA PET-CT scans were reanalyzed for tumor node metastases staging and risk stratification of lymph node and distant metastasis proportion. Histopathology of 23/97 patients was available as gold standard. Chi-square test was used for proportion comparison. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), overestimation, underestimation, and correct estimation of T and N stages were calculated. Kappa coefficient (κ) was derived for inter-rater agreement. Lymph node or distant metastasis detection on PSMA PET/CT increased significantly with increase in risk category. PSMA PET/CT sensitivity, specificity, PPV, and NPV for extraprostatic extension, seminal vesicle invasion, and lymph node metastases were 63.16%, 100%, 100%, 36.36%; 55%, 100%, 100%, 25%; and 65.62%, 99.31%, 87.50%, and 97.53%, respectively. Kappa coefficient showed substantial agreement between PSMA PET/CT and histopathological lymph node metastases (κ = 0.734); however, it was just in fair agreement (κ = 0.277) with T stage. PSMA PET/CT overestimated, underestimated, and correct estimated T and N stages in 8.71%, 39.13%, 52.17% and 8.71%, 4.35%, and 86.96% cases, respectively. PSMA PET/CT has potential for initial risk stratification with reasonable correct N stage estimation, however underestimates T stage. Hence, we concluded that PSMA PET/CT should be used as " first-stop-shop" for staging and initial risk stratification of PCa with regional magnetic resonance imaging in surgically resectable cases.
31
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Ian M. Thompson, J. Brantley Thrasher, Gunnar Aus et al. · The Journal of Urology · 2007 · 1.1K citations
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium
Alan W. Partin, Leslie A. Mangold, Dana M Lamm et al. · Urology · 2001 · 1K citations
Ali Afshar‐Oromieh, Eleni Avtzi, Frederik L. Giesel et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 974 citations · Full text
Medicine, Nuclear Medicine, Oncology +17